×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
COCP – cocrystal pharma, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
COCP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/19
08:27 am
cocp
Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 [Yahoo! Finance]
Neutral
Report
Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 [Yahoo! Finance]
2/19
08:00 am
cocp
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
Neutral
Report
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
12/18
08:17 am
cocp
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus [Yahoo! Finance]
Medium
Report
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus [Yahoo! Finance]
12/18
08:00 am
cocp
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Medium
Report
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/25
04:10 pm
cocp
Form 4 Cocrystal Pharma, Inc. For: Feb 24 Filed by: FROST PHILLIP MD ET AL
Neutral
Report
Form 4 Cocrystal Pharma, Inc. For: Feb 24 Filed by: FROST PHILLIP MD ET AL
2/19
08:31 am
cocp
Form 8-K Cocrystal Pharma, Inc. For: Feb 19
Neutral
Report
Form 8-K Cocrystal Pharma, Inc. For: Feb 19
2/9
04:10 pm
cocp
Form 4 Cocrystal Pharma, Inc. For: Feb 06 Filed by: FROST PHILLIP MD ET AL
Low
Report
Form 4 Cocrystal Pharma, Inc. For: Feb 06 Filed by: FROST PHILLIP MD ET AL
1/15
04:11 pm
cocp
Form 8-K Cocrystal Pharma, Inc. For: Jan 09
Low
Report
Form 8-K Cocrystal Pharma, Inc. For: Jan 09
1/13
05:04 pm
cocp
Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: Kornberg Roger D.
Medium
Report
Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: Kornberg Roger D.
1/13
04:10 pm
cocp
Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: Lee Sam
Medium
Report
Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: Lee Sam
1/13
04:10 pm
cocp
Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: FROST PHILLIP MD ET AL
Medium
Report
Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: FROST PHILLIP MD ET AL
1/13
04:10 pm
cocp
Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: Hassan Fred
Medium
Report
Form 4 Cocrystal Pharma, Inc. For: Jan 09 Filed by: Hassan Fred
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/18
Form 8-K Cocrystal Pharma, Inc. For: Feb 18
5.6%
4/15 Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit 7.5%
10/29 Form 4 Cocrystal Pharma, Inc. For: Oct 23 Filed by: Schinazi Raymond F 7.5%
2/28 Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market 8.6%
2/27 Form SC 13G Cocrystal Pharma, Inc. Filed by: SABBY MANAGEMENT, LLC 9.4%
1/31 Form 8-K Cocrystal Pharma, Inc. For: Jan 29 10.0%
3/11 Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market 11.5%
10/16 Is Cocrystal Pharma, Inc. (NASDAQ:COCP) Overpaying Its CEO? [Yahoo! Finance News] 14.5%
3/6 Cocrystal Pharma Announces Plans to Advance Coronavirus Program 18.6%
2/24 Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds 129.3%
4/15 Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit 7.5%
10/29 Form 4 Cocrystal Pharma, Inc. For: Oct 23 Filed by: Schinazi Raymond F 7.5%
2/28 Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market 8.6%
2/27 Form SC 13G Cocrystal Pharma, Inc. Filed by: SABBY MANAGEMENT, LLC 9.4%
1/31 Form 8-K Cocrystal Pharma, Inc. For: Jan 29 10.0%
3/11 Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market 11.5%
10/16 Is Cocrystal Pharma, Inc. (NASDAQ:COCP) Overpaying Its CEO? [Yahoo! Finance News] 14.5%
3/6 Cocrystal Pharma Announces Plans to Advance Coronavirus Program 18.6%
2/24 Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds 129.3%
TOP News Decliners
2/27
Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market
-12.9%
8/9 Form 10-Q Cocrystal Pharma, Inc. For: Jun 30 -12.2%
3/30 Form 8-K Cocrystal Pharma, Inc. For: Mar 30 -10.3%
2/3 COCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERING -13.3%
3/13 Form 8-K Cocrystal Pharma, Inc. For: Mar 09 -14.8%
1/29 COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING -16.9%
4/22 Form 8-K Cocrystal Pharma, Inc. For: Apr 19 -26.6%
11/12 Form 10-Q Cocrystal Pharma, Inc. For: Sep 30 -26.8%
3/9 Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market -30.7%
10/30 COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK -35.5%
8/9 Form 10-Q Cocrystal Pharma, Inc. For: Jun 30 -12.2%
3/30 Form 8-K Cocrystal Pharma, Inc. For: Mar 30 -10.3%
2/3 COCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERING -13.3%
3/13 Form 8-K Cocrystal Pharma, Inc. For: Mar 09 -14.8%
1/29 COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING -16.9%
4/22 Form 8-K Cocrystal Pharma, Inc. For: Apr 19 -26.6%
11/12 Form 10-Q Cocrystal Pharma, Inc. For: Sep 30 -26.8%
3/9 Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market -30.7%
10/30 COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK -35.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: